Model based PEEP titration versus standard practice in mechanical ventilation: A randomised controlled trial by Kim KT et al.
STUDY PROTOCOL Open Access
Model-based PEEP titration versus standard
practice in mechanical ventilation: a
randomised controlled trial
Kyeong Tae Kim1* , Sophie Morton1, Sarah Howe1, Yeong Shiong Chiew2, Jennifer L. Knopp1, Paul Docherty1,
Christopher Pretty1, Thomas Desaive3, Balazs Benyo4, Akos Szlavecz4, Knut Moeller5, Geoffrey M. Shaw6 and
J. Geoffrey Chase1
Abstract
Background: Positive end-expiratory pressure (PEEP) at minimum respiratory elastance during mechanical
ventilation (MV) in patients with acute respiratory distress syndrome (ARDS) may improve patient care and
outcome. The Clinical utilisation of respiratory elastance (CURE) trial is a two-arm, randomised controlled trial (RCT)
investigating the performance of PEEP selected at an objective, model-based minimal respiratory system elastance
in patients with ARDS.
Methods and design: The CURE RCT compares two groups of patients requiring invasive MV with a partial
pressure of arterial oxygen/fraction of inspired oxygen (PaO2/FiO2) ratio ≤ 200; one criterion of the Berlin consensus
definition of moderate (≤ 200) or severe (≤ 100) ARDS. All patients are ventilated using pressure controlled (bi-level)
ventilation with tidal volume = 6–8 ml/kg. Patients randomised to the control group will have PEEP selected per
standard practice (SPV). Patients randomised to the intervention will have PEEP selected based on a minimal
elastance using a model-based computerised method. The CURE RCT is a single-centre trial in the intensive care
unit (ICU) of Christchurch hospital, New Zealand, with a target sample size of 320 patients over a maximum of 3
years. The primary outcome is the area under the curve (AUC) ratio of arterial blood oxygenation to the fraction of
inspired oxygen over time. Secondary outcomes include length of time of MV, ventilator-free days (VFD) up to 28
days, ICU and hospital length of stay, AUC of oxygen saturation (SpO2)/FiO2 during MV, number of desaturation
events (SpO2 < 88%), changes in respiratory mechanics and chest x-ray index scores, rescue therapies (prone
positioning, nitric oxide use, extracorporeal membrane oxygenation) and hospital and 90-day mortality.
Discussion: The CURE RCT is the first trial comparing significant clinical outcomes in patients with ARDS in whom
PEEP is selected at minimum elastance using an objective model-based method able to quantify and consider both
inter-patient and intra-patient variability. CURE aims to demonstrate the hypothesized benefit of patient-specific
PEEP and attest to the significance of real-time monitoring and decision-support for MV in the critical care
environment.
Trial registration: Australian New Zealand Clinical Trial Registry, ACTRN12614001069640. Registered on 22
September 2014.
(https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=366838&isReview=true) The CURE RCT clinical
protocol and data usage has been granted by the New Zealand South Regional Ethics Committee (Reference
number: 14/STH/132).
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Background
Mechanical ventilation (MV) support is crucial for patients
with acute respiratory distress syndrome (ARDS). While
there is agreement on the preference for lower tidal vol-
umes [1, 2], there is relatively little consensus on the selec-
tion of positive end-expiratory pressure (PEEP) [3–9].
Traditionally, lower PEEP has been used [10, 11], but low
PEEP can lead to increases in oxygen desaturation and hyp-
oxaemia [4, 12] and worsening of lung injury, indicated by
greater use of rescue therapies and deaths after rescue ther-
apy [9]. High PEEP can increase alveolar recruitment, but
can decrease cardiac output and lead to further lung injury
due to barotrauma and/or volutrauma [13] or overdisten-
sion [4, 9].
PEEP can be optimised to reduce hypoxaemia [6] and
intrapulmonary shunting [7] and improve gas exchange [8]
and oxygenation [4, 14, 15], by maintaining recruitment of
injured or collapsed alveoli [13]. In patients with ARDS,
PEEP reduces ventilator-induced lung injury (VILI) [4, 9],
increases recruitment [14–16], and reduces inflammatory
mediators in plasma and bronchoalveolar lavage fluid [8].
MV strategies combining low tidal volumes with recruit-
ment manoeuvres (RMs) and higher PEEP to prevent VILI
have been hypothesized as ideal for lung protection [6, 17].
However, currently, there is still no standardized approach
to the selection of this optimal PEEP, or to deciding how
often PEEP should be adjusted or recalculated.
Reports from experimental animal trials performed by
Carvalho et al., Suarez-Sipmann et al. and Lambermont
et al. [18–20] indicate that pigs induced with ARDS ex-
perience minimal respiratory elastance at a specific PEEP
associated with higher oxygenation, maximum recruit-
ment, and higher functional residual capacity, all without
signs of lung overdistension. Equally, it has been pro-
posed that PEEP should be set whereby the lung has
minimal respiratory elastance (or maximum compli-
ance), which could be clinically beneficial by balancing
the risks of PEEP that is set too low or too high [21–23].
Aside from the work by Suter et al. [21], Pintado et al.
also showed that PEEP selection at minimal elastance is
beneficial to patients [22]. Despite some consistent find-
ings, the application of minimal elastance PEEP selection
remains limited and hindered by the lack of an objective,
reliable, and easy-to-use method to determine elastance
at the bedside in real time.
Chiew et al. showed the potential benefit of minimal-
elastance PEEP selection in a pilot study [23, 24]. Following
the study, a phase-2 randomised controlled trial (RCT) was
designed to assess mechanical ventilation at minimal elas-
tance PEEP in patients with ARDS versus standard practice
of care in a single-centre hospital. In particular, patient-
specific respiratory system elastance and corresponding
minimal elastance PEEP is determined using a validated
model-based method and computer software [25]. This
trial uses real-time-identified patient-specific respiratory
system elastance, and thus the trial is named the Clinical
utilisation of respiratory elastance (CURE) RCT. This
manuscript presents the detailed clinical protocol for the
phase-2 CURE RCT. This trial is registered with the Aus-
tralian New Zealand Clinical Trial Registry (ANZCTR):
ACTRN12613001006730.
Methods and trial design
Study design and setting
The CURE RCT is a two-arm RCT comparing model-
based mechanical ventilation (MBV) with current stand-
ard practice mechanical ventilation (SPV) in patients
with a ratio of partial pressure of arterial blood oxygen
(PaO2)/fraction of inspired oxygen (FiO2) (P/F
ratio) ≤ 200. It is to be conducted in a single-centre hos-
pital intensive care unit (ICU) at Christchurch Hospital in
Christchurch, New Zealand.
The primary objective is to assess the impact of
model-based ventilation in PEEP selection (MBV)
therapy on clinically significant patient outcomes and
patient-centred quality of care metrics. The other objec-
tives of this study include (1) to provide the knowledge
and methods to make care more patient-specific and
timely to optimise treatment and improve outcomes in a
large cohort of critically ill patients and (2) to improve
the understanding of the pathophysiological basis of cri-
tical illness through what we learn about the hourly and
daily evolution of lung injury in terms of patient-specific
elastance and response to care through this study.
The primary outcome of this study is the area under
the curve (AUC) of PaO2/FiO2 over the period of mech-
anical ventilation. Secondary outcomes include length of
time of MV (LoMV), ventilator-free days (VFD) up to
28 days, ICU and hospital length of stay (LoS), AUC of
SpO2 (oxygen saturation)/FiO2 during MV, number of
desaturation events (frequency and fraction of time
SpO2 < 88%), changes in respiratory mechanics and
chest x-ray index scores, rescue therapies (prone posi-
tioning, nitric oxide use, extracorporeal membrane oxy-
genation (ECMO)) and hospital and 90-day mortality.
These outcomes and their corresponding four levels of
specification based on Zarin et al., 2011 is shown in
Table 1. The secondary analysis includes comparison of
the means of LoMV, VFD, hospital and ICU LoS, 90-day
mortality, chest x-ray index scores and rescue therapies
used.
A difference in primary and secondary outcomes will
show the impact of MBV compared to SPV. No differ-
ence would show that enhanced, model-based metrics of
patient-specific condition have no effect on patient-
centred or clinical outcomes. Either outcome will yield
clinical guidance.
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Two-arm RCT
Eligible patients are randomised to either the model-
based intervention group (MBV) or the control group
(SPV). Both groups will have designated computer soft-
ware to monitor their breathing [25]. The software uses
real-time measurements of pressure and flow from the
ventilator to objectively calculate the patient-specific and
breath-specific respiratory system elastance for every
breath [25].
Participants on MBV will undergo recruitment ma-
noeuvres (RM), an initial maximum recruitment
manoeuvre (RMMax) or subsequent PEEP adjustment
and monitoring procedure (PUMP) mini recruitment
manoeuvres. The respiratory elastance at each PEEP step
during these protocolised RMs is calculated and re-
corded. The software will recommend a patient-specific
minimal-elastance PEEP to the clinicians in setting ven-
tilator PEEP. Patients on SPV will have PEEP selected
using current clinical practice without the aid of the
software, but all breaths will be analysed and elastance
recorded; clinical staff will be blinded to these data.
Adherence to the intervention
Patients recruited into this study will be under constant
supervision in the ICU. However, their outcomes will be
measured based on the intention-to-treat principle, tak-
ing into account protocol variations, which naturally
occur. These variations will be reported to the primary
investigator at the earliest opportunity and followed up.
There will be detailed training on the use of CURE
equipment and on the protocol, to allow adherence
to trial.
Protocol amendments
This trial is based on the intention-to-treat principle.
Thus, protocol amendments may be required to ensure
patient safety and outcomes, and the primary investiga-
tors will instigate protocol amendments if necessary.
The amendments will be reviewed by the data monitor-
ing committee (DMC) to warrant patient safety and out-
comes. The DMC may also refer protocol amendments
based on outcomes of the interim analysis reports.
Finally, if participant enrolment is slow, the protocol
may be amended to allow faster recruitment.
Concomitant care and intervention
The trial involves critically ill participants who are
mechanically ventilated. Thus, it is likely and acceptable
for participants to be receiving medication related to any
other concomitant comorbid conditions while partici-
pating in the CURE RCT.
Participants in this study will not be concomitant to an-
other study that would affect the results of this study. Par-
ticipants will not be co-enrolled in another study that uses
different oxygenation settings, recruitment manoeuvre
procedures or anything that may affect the outcomes of
this study.
Eligibility criteria
The following are the CURE RCT inclusion, exclusion
and P/F ratio criteria.
Inclusion criteria
The inclusion criteria are:
1. P/F ratio ≤ 200
i. on any level of PEEP or FiO2, or
ii. P/F ratio ≤ 200 on FiO2 = 50% and PEEP = 5 (see
“P/F ratio criteria”)
Exclusion criteria
The exclusion criteria are:
1. P/F ratio > 300 on any level of PEEP or FiO2
2. P/F ratio > 200 on FiO2 = 50% and PEEP = 5
3. Ventilated > 48 h (including time spent in another
hospital)
4. Not expected to be ventilated for another 48 h
5. Age < 16 years
6. Any medical condition associated with a clinical
suspicion of raised intracranial pressure and/or
measured intracranial pressure ≥ 20 mmHg
7. High spinal cord injury with loss of motor function
and/or significant weakness due to neurological
disease
8. Barotrauma (pneumothorax, pneumomediastinum,
subcutaneous emphysema or any intercostal
catheter for the treatment of air leak)
9. Asthma as the primary presenting condition or
history of significant chronic obstructive pulmonary
disease
10. Moribund and/or not expected to survive for > 72 h
11. Agreed limitations of care due to co-morbidities, or
not expected to survive 90 days
12. Lack of clinical equipoise as determined by ICU
medical staff managing the patient (for example, if
the patient has unremarkable findings on chest
x-ray, with the possibility of thrombotic or fat
pulmonary emboli)
13. Previous enrolment in the CURE RCT
P/F ratio criteria
The P/F ratio criteria are:
1. If the P/F ratio is ≤ 200, the patient is eligible for
enrolment
2. If 200 < P/F ratio ≤ 300, set FiO2 = 50% and PEEP =
5 cmH2O and repeat the analysis of arterial blood
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gases (ABG) within 10 min of the change to
measure the new P/F ratio
a. If the new P/F ratio is ≤ 200, the patient is
eligible for enrolment
b. If the new P/F ratio is > 200, the patient is not
eligible for enrolment and, if appropriate, will be
re-screened at a later time
This trial will recruit patients who have a P/F ratio ≤
200, a criterion in the definition of severe to moderate
ARDS as defined by the ARDS Definition Task Force in
the Berlin definition [26]. They will be eligible if their P/
F ratio is ≤ 200 on any level of PEEP and FiO2. Those
patients with a 200 < P/F ratio ≤ 300 will be placed on
PEEP = 5 cmH2O, and FiO2 = 50%. If a subsequent P/F
ratio is ≤ 200 they will also become eligible (see Add-
itional file 1). The P/F ratio measured at FiO2 of 50%
and PEEP of 5cmH2O is based on Villar et al. 2013 [27].
Consent, compliance and withdrawal
Consent procedure
First, it is important to note that standard ventilation
practice may include recruitment manoeuvres to in-
crease lung recruitment and oxygenation. However,
these clinical practices are widely variable and often not
standardised. The recruitment techniques used to im-
prove oxygenation and mechanics of ventilation in the
intervention and control arms of this study are within
the scope of standard ICU clinical practice. The proto-
cols used will standardise these existing interventions to
recruit lung volume and titrate PEEP.
Study participants will be unable to consent to partici-
pation in this study prior to enrolment as they will be
sedated and mechanically ventilated. It is also equally
important to randomise participants to either arm of the
RCT at the commencement of MV to ensure a fair com-
parison. Patients who have been ventilated ≤ 48 h are eli-
gible for the CURE RCT. Given this time frame, the
CURE RCT will recruit patients once family consent is
obtained. However, if the treating clinician firmly be-
lieves a recruitment manoeuvre is in the best interests of
the patient, and no family is available for consent, the
participant will be enrolled and randomised and the
appropriate protocolised recruitment manoeuvre will
follow. In this case, delayed consent is obtained as early
as possible. Once the participant recovers from their
condition and is discharged from the ICU, we will seek
their informed consent.
In cases where the family cannot attend the hospital to
sign a statement of assent, their opinion will be obtained
by telephone in the first instance. Information about the
study will either be made available by emailing them the
information sheet and contacting them later by tele-
phone, or the information sheet will be read to them
over the telephone. The telephone conversation(s) and
their opinions will be documented in the patient’s med-
ical record. As soon as the family is able to attend the
hospital, they will be asked to sign the statement. If the
family are not able to sign a statement during the pa-
tient’s time in the ICU, they have the option of printing
out the statement, signing it, and mailing, emailing or
faxing it back. The sample study information and consent
forms can be seen in Additional file 2.
Withdrawal of consent
If the participant’s family, relative or friend does not
agree to their continued participation, they will be with-
drawn from the study and we will seek agreement from
them to use information related to mechanical ventila-
tion that was collected up until that point.
If a participant chooses to withdraw from the trial, we
also will seek agreement to use information related to
mechanical ventilation that was collected up until that
point. If they do not agree, then all study information
obtained will be destroyed.
Randomisation and blinding
Participants will be block-randomised, with block sizes gen-
erated using a randomisation programme. The programme
will randomly assign patients into either a control group or
intervention group through a random block size (the block
size is 4, 6, 8 or 10 patients). Eligible and consented patients
will be block-randomised in a ratio of 1:1. No effort will be
made to stratify the subgroups considered in the secondary
analyses. By the nature of the intervention, CURE cannot
be double-blinded. Un-blinding is not applicable due to the
nature and setting of the intervention.
All patient data collected are de-identified using a sin-
gle patient numbering system. Patients are assigned to a
study number to ensure no bias in the results. This sys-
tem will be a simple incrementing scheme, such that pa-
tients randomised into the CURE trial are identified as
study-001, study-002, etc.
Ventilation settings, oxygenation, and patient positioning
Tidal volumes (VT) and driving pressures (DP) during MV
The VT is adjusted to 6–8 ml/kg per ideal body weight
(IBW), and the maximum minute ventilation (VEmax) to
≤ 0.2 L/kg/min. The IBW is measured using the patient’s
height and look-up table at the bedside or is calculated
using the formulae:
Men : 50þ 0:91 height cm½ −152:4ð Þ kg ð1Þ
Women : 45:5þ 0:91 height cm½ −152:4ð Þ kg ð2Þ
The DP is the plateau pressure (PPlat) minus the PEEP.
In patients with very severe ARDS the adjustment of VT
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to 6–8 ml/kg IBW may be injurious if the DP is higher
than 15 cmH2O. A DP ≤ 15 cmH2O was associated with
better patient survival when assessed using a multilevel
mediation analysis of 3562 patients in nine RCTs of
ARDS [28]. Therefore, the DP will be limited to ≤ 15
cmH2O at all times. In addition, during spontaneous
ventilation, pressure support will be limited to ≤ 15
cmH2O.
The ventilation rate is set between 12 and 20 breaths
per minute. The aim is to keep the plateau pressure
Pplat ≤ 30 cmH2O. If necessary, VT may be reduced to as
low as 4 ml/kg and the respiratory rate (RR) kept at ≤ 30
breaths per minute. CO2 will frequently rise in severe
lung injury (permissive hypercapnia) when patients are
mechanically ventilated within these guidelines. How-
ever, if CO2 is ≥ 80mmHg or increased by ≥ 50% in the
previous 4 h, the intensive care specialist on duty will be
notified, and they may choose to deviate from these
guidelines.
Ventilation mode
All patients enrolled are to be ventilated using a pressure-
controlled mode, for example, the Bi-Level ventilation
mode on the Puritan Bennett PB840 ventilator (Covidien,
Boulder, CO, USA) or PC-SIMV+ on the Dräger Evita® In-
finity® V500. Patients will be ventilated using Bi-Level/PC-
SIMV+ mode, which allows unrestricted spontaneous
breathing efforts to lessen ventilator dyssynchrony. How-
ever, during any recruitment manoeuvre procedures, syn-
chronized intermittent mandatory ventilation (SIMV)
with pressure-controlled (PC) ventilation is used and
returned to original mode afterwards. Should patients
already be ventilated using a ventilator incompatible with
the CURE computer system, they will have their ventilator
changed to a compatible ventilator for the trial. Patients
will be transitioned to assisted spontaneous breathing
(ASB) if they meet the weaning criteria (see “Weaning”).
In severe ventilator dyssynchrony, a very high respira-
tory drive may result in sub-atmospheric circuit pres-
sures and risk of aspiration of gastric contents around
the endotracheal cuff. If a participant has a high respira-
tory drive on Bi-Level/PC-SIMV+ ventilation, producing
a fall in airway pressure during inspiration, muscle relax-
ants will be considered to facilitate controlled breathing.
However, if the clinician feels the participant may bene-
fit from breathing spontaneously, transition to ASB may
be made if they substantially meet the weaning criteria
(see “Weaning”).
However, spontaneous breathing efforts may mask
high trans-pleural pressures and produce high levels of
regional lung strain. Oesophageal pressure will not be
measured during this trial. If the treating clinician is
concerned about patient self-inflicted lung injury (P-
SILI) [29, 30], they will consider using muscle relaxants
to control ventilation.
Patients will not undergo any procedures using a
cough-assist machine prior to weaning and transitioning
to spontaneous breathing. However, the treating clin-
ician may use a cough-assist machine to aid secretion re-
moval (during spontaneous breathing) if they believe it
is in the patient’s best interests. Finally, in any circum-
stances where the patient is planned to be temporarily
disconnected from the ventilator, their endotracheal
tube will be clamped to prevent de-recruitment.
SpO2 targets
To ensure a fair comparison, all CURE study partici-
pants will have inspired oxygen levels titrated to achieve
the following pulse oximetry saturations:
i. SpO2 = 93–95% if FiO2 is less than 60%
ii. SpO2 = 90–92% if FiO2 is greater than or equal to
60%
The aim is to spend greater than or equal to 90% of
time in the target range. The FiO2 should only be in-
creased above 21% if these targets are not met, using 5%
increments starting with a FiO2 = 25%. There is natural
variability in SpO2. To avoid toggling between two FiO2
levels, 10 min of settling time will be allowed before
changing the FiO2. The best FiO2 is chosen to keep the
saturation within the specified targets ranges over 90%
of the time.
Patient position, turning and prone positioning
Patients are kept at 30° head up whenever possible. This
position maximises recruitment of the lung and may re-
duce the risk of aspiration. Wherever possible, patients
should be rolled from supine to right-side down, back to
supine, then to left-side down. This turning of patients
is ideally performed every 3 h.
Transient hypoxaemia frequently occurs after a patient
has been turned and may be worse if there is inadequate
PEEP. Hypoxaemia may also become more severe if par-
ticipants are rolled from left-side down to right-side down
due to cyclical de-recruitment of the non-dependent lung
and re-recruitment of the dependent lung. This cyclical
de-recruitment of the lung has the potential to contribute
to VILI. Thus, patients with severe lung injury may be
very intolerant of being turned. In some instances, the
lungs may need to be re-recruited. If desaturation does
occur, this will be recorded as a serious adverse event
(SAE).
Prone positioning of patients may be considered if the
P/F ratio is ≤ 100 and FiO2 ≥ 60%. Patients randomised
to the intervention arm (MBV) may still undergo a pro-
tocolised recruitment manoeuvre. For patients in the
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standard practice ventilation arm (SPV) a staircase
recruitment manoeuvre is left to clinical judgement.
ABG recordings
The primary outcome of this trial is the AUC of the P/F
ratio. For this reason, mandatory daily ABG recordings
are performed for up to 10 days after enrolment. ABGs
are taken around 0600 hours and 1800 hours. The ABGs
are also acquired within 60 min of any recruitment
manoeuvre procedure and 30–60min after the recruit-
ment manoeuvre procedure. The added ABGs from RM
procedures will be used in secondary analysis, but will
be omitted during primary analysis to ensure the same
number of data points per day for all patients.
Duration of the intervention
Patients randomised to the model-based ventilation
(MBV) cohort will remain in the protocol up to 10 days.
Thereafter, they will receive the same care as participants
assigned to standard practice ventilation (SPV). However,
if participants have been extubated, but then require in-
tubation and re-ventilation at any time within 10 days of
enrolment, they will return to the original assigned proto-
col (MBV or SPV). All patients will receive standard care
beyond 10 days of enrolment, and their data, including
ABG recordings, will continue to be collected for up to
28 days. This intervention schedule is shown in Fig. 1.
General procedures
Procedures for the control group (SPV)
The procedures are as follows:
1. PEEP is selected as per standard practice.
2. The decision to carry out a staircase recruitment
manoeuvre will be based on clinical judgement. The
protocol for performing the staircase recruitment
manoeuvre is explained in “Recruitment
manoeuvres (RM)”.
3. ABGs will be taken twice daily.
4. Ventilator data are collected continuously until the
ventilator is disconnected.
Procedures for the intervention group (MBV)
The procedures are as follows:
1. For patients included in the MBV (intervention)
group, the PEEP and MV will be guided by
clinicians using bedside computers, while
maintaining VT and FiO2.
Fig. 1 Trial assessment schedule
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2. Patients randomised to MBV will undergo
protocolised recruitment manoeuvres (RM)
i. Before the RM, the patient should be sedated
and paralysed, if required, with muscle relaxants
to prevent spontaneous breathing efforts.
ii. The first RM used is a maximum recruitment
manoeuvre (RMMax). This is done at the
beginning of the trial by clinicians and only
repeated if clinically indicated.
iii. The PEEP adjustment and monitoring
procedure is referred to as a “PUMP”, whereby
the PEEP is adjusted − 4 cmH2O to + 4 cmH2O
of the current PEEP setting. The PUMP may be
performed by ICU staff trained in this
technique.
3. The participant will no longer undergo a PUMP
when:
a. FiO2 ≤ 35%,
i. And they have fully transitioned to
spontaneous breathing
ii. And the PaO2 was ≥ 60 mmHg for the last
24 h, or
b. After 10 days from study enrolment, or
c. At the discretion of the clinician, for example:
iii. When they have a new neurological
condition.
iv. They are awake and breathing normally
without evidence of respiratory distress, and
where sedation (with or without paralysis) is
not considered to be in their best interests.
4. ABGs will be recorded twice daily and before and
after any recruitment procedure.
5. Data will be collected continuously until the patient
is disconnected from the ventilator.
Recruitment manoeuvres (RM)
Patients enrolled in this study will undergo RMs. The
RMs are only carried out by senior medical staff or se-
nior trainees familiar with this technique. RMMax and
PUMPs are for participants randomised to the MBV
protocol arm only. Patients assigned to the SPV arm
may undergo a staircase RM (SRM) at the discretion of
the treating clinician according to standard practice. (see
“Standard practice staircase recruitment manoeuvre”).
All RMs will be performed in SIMV pressure con-
trolled (PC) ventilation mode. The peak inspiratory pres-
sure (Pi) is set to achieve a VT of 6–8ml/kg IBW.
Preferably, VT should result in DP ≤ 15 cmH2O above
PEEP.
Before and after each RM, ABGs (pH, PaCO2, PaO2,
HCO3), SpO2, end-tidal CO2 partial pressure (ETCO2),
FiO2, PEEP, RR), and VT will be recorded. In addition, dur-
ing the RMmax (model-based ventilation arm) or (standard
practice ventilation (SRM) arm, at each PEEP increment,
Heart rate, rhythm, mean arterial pressure (MAP), SpO2,
FiO2, VT, RR, ETCO2 and rates of use of vasoactive drugs
will be recorded. This data will be valuable in assessing the
safety of the RMMax, PUMP and SRM.
In many cases, where the lung stiffness, or respiratory
elastance (E) is high, it will not be possible to deliver a
VT of 6 ml/kg IBW. Furthermore, during the RM, the
delivered VT may fall further as the elastance increases.
As a result, it may be necessary to increase the respira-
tory rate to accommodate the reduction in minute
ventilation. For example, if E is > 40 cmH2O/L (or com-
pliance < 25 ml/cmH2O) in a patient weighing 58 kg
(IBW), (normal range 15–20 cmH2O/L), the VT will be
< 6 ml/kg (< 350 ml) when the driving pressure is
15 cmH2O.
It is important that oxygenation targets in both arms
are carefully followed to ensure a fair comparison be-
tween them. The SpO2 will be kept in the target range
prior to any RM. This approach allows small decreases
in oxygenation to be detected during the decremental
PEEP phase of the recruitment manoeuvre, while also
providing a sufficient buffer in the event of significant
de-saturation due to ventilation perfusion (V/Q) mis-
match. V/Q mismatch increases with higher airway pres-
sures when pulmonary arterial blood is shunted away
from the pulmonary capillaries by-passing aerated re-
gions of the lung.
RM checklist
Before performing any RM, the following criteria are
considered. Any RM must be delayed until these condi-
tions are corrected in the consideration of the following
at-risk patient conditions:
1. Haemodynamic instability (e.g. ongoing
haemorrhage).
2. Not optimally resuscitated with fluids (e.g. stable
blood pressure, but pulse pressure variation ≥ 12%
because of inadequate left ventricular preload)? This
is only applicable in the absence of spontaneous
breathing.
3. Evidence of barotrauma since enrolment?
a. If there is new barotrauma, RMs must not be
attempted and the participant will be withdrawn
from trial. They will continue to be observed
and followed up. A SAE will be reported.
RM preparation steps
Once the RM checklist conditions are met, the patient
can be prepared for a RM by ensuring:
1. There is a reliable arterial line.
2. The patient is supine, 15–30° head up.
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3. The endotracheal tube (ETT) cuff is inflated to 45
cmH2O (RMMax or SRM) or 35–40 cmH2O
(PUMP) to ensure there is no leak at maximum
airway pressures. The ETT cuff is deflated to less
than 30 cmH2O at the end of the RM procedures.
4. The peak pressure alarm is set to 45 cmH2O
(RMMax, PUMP, SRM)
5. SpO2 is in the target range (FiO2 < 60%: 93–95% or
FiO2 ≥ 60%: 90–92%), and ABGs have been
recorded within the last 60 min.
6. If the patient is not on vasoactive drugs,
intravenous (i.v.) adrenaline (or other suitable
vasoactive drug) is available in the event of
hypotension.
RM termination
RMs should be terminated if at any time during the RM
any of the following changes persist for more than
3 min:
1. Desaturation, with SpO2 < 88%.
2. New bradycardia (heart rate < 60 beats per minute)
or,
3. New tachycardia (heart > 140 beats per minute) or,
4. New arrhythmia leading to new bradycardia (2) or
new tachycardia (3) or,
5. New hypotension (reduction in MAP by 40% or
MAP < 60 mmHg).
This RM termination criteria applies to all RM proce-
dures in both arms.
RMMax; MBV
The RMMax is a computer-guided staircase RM proced-
ure in the MBV intervention arm. This method is de-
signed to safely increase the inspiratory pressure to a
maximum airway pressure of 40–43 cmH2O, with DP
limited to 15 cmH2O, and maximum PEEP limited to
25–28 cmH2O. The RMMax is guided by the CURE soft-
ware using a validated model-based method, which esti-
mates elastance to determine the optimal PEEP [23, 31].
The RMMax is carried out by intensive care specialists
or senior trainees familiar with this technique. This pro-
cedure is only carried out during working hours (0800–
1800 hours), but preferably within 4–6 h of enrolment.
However, for patients enrolled overnight, unless there
are compelling reasons to carry out an RMMax, this pro-
cedure may be delayed till the following morning (0800
hours).
Contra-indicated preconditions to an RMMax are ex-
cluded using the RM checklist. If it is safe to proceed,
the patient is prepared for the RMMax.
The following instructions are given to the clinician:
1. Adjust oxygenation to meet the target range.
2. Titrate sedation so the patient is not verbally
responsive and has loss of their eyelash reflex. Use
fentanyl or morphine increments with propofol to
provide a “balanced” deeper sedation level. Give
rocuronium 1.0–1.5 mg/kg through a reliable i.v.
line; ensure the line is flushed.
3. Set the ventilator to SIMV-PC (pressure control)
mode.
4. Set peak inspiratory pressure (Pi) to 15 cmH2O
above PEEP.
5. Ensure the initial PEEP is ≤ 15 cmH2O.
6. Start maximum recruitment on the CURE soft
programme.
7. Follow the steps of the CURE soft protocol: during
the RMMax, increase PEEP in steps of 4 cmH2O
above the baseline PEEP level until Pi reaches 40–
43 cmH2O or PEEP 25–28 cmH2O. Then reduce
PEEP in 4 cmH2O decrements until the original
starting PEEP is reached. Adjust FiO2 throughout
the procedure to keep SpO2 ≥ 90%.
8. Once PEEP has been returned to the initial setting,
perform a second RMmax using the same method in
point 7. The RMMax is carried out twice. During the
first RMMax the elastance changes in PEEP level are
more variable and therefore less predictable. The
non-recruited lung is highly heterogeneous with
regions of collapse and consolidation. The first
RMMax is used to recruit these de-recruited regions.
The second manoeuvre is used to estimate optimal
PEEP from repeated estimates of elastance changes
during decremental PEEP titration.
9. The CURE soft programme will recommend an
optimal PEEP at the end of the second RMMax. You
may either accept this computerised
recommendation, or reject it (with a reason) if you
feel the new PEEP level is inappropriate. If rejected,
record your reason(s) on the programme.
10. Return the patient to the previous ventilation mode.
11. Adjust VT to ≤ 6–8 ml/kg IBW. If the plateau
pressure is > 30 cmH2O, adjust the VT down to 4–
6 ml/kg IBW and tolerate permissive hypercapnia.
Also ensure that the DP remains at ≤ 15 cmH2O.
You may increase the respiratory rate up to 30
breaths/min provided there is no significant auto-
PEEP causing breath stacking.
12. Reduce the ETT cuff pressure to the previous level
and re-set ventilator alarms to previous settings.
13. Record ABGs 30–60 mins after conclusion of the
procedure.
Repeating the RMMax
The RMMax may be repeated only when the following
conditions are met:
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1. If there is a significant change in the participant’s
condition, e.g. new severe hypoxaemia (SpO2 < 90%
and FiO2 ≥ 60%; P/F ~ 100) and
2. Patient conditions for which lung recruitment is
contraindicated are excluded (e.g. endobronchial
intubation, mucous plugging, pneumothorax etc)
and
3. Analgesia and sedation and patient position have
been optimised (consider small changes to
respiratory rate, VT and pressure support, or a
rocuronium infusion) and
4. The PUMP fails to improve oxygenation
PUMP: PEEP adjustment and monitoring procedure
PUMP is a regular mini-recruitment manoeuvre proced-
ure designed to adjust PEEP based on patient-specific
changes in condition. This mini-RM is also guided by
CURE software and moves between ±4 cmH2O from the
current PEEP. PUMP should be performed twice daily
during normal working hours (0800–1800 hours) or at
any other time if lung de-recruitment is considered to
be the likely cause of new desaturation. The Pi will be
left the same as in the current ventilator settings. To en-
sure a PUMP can be safely carried out, the RM checklist
and preparation steps are to be followed. If the checklist
preconditions are met, the PUMP may be carried out.
The following instructions are given to the clinician:
1. Titrate sedation so the patient is not verbally
responsive and has loss of their eyelash reflex. Use
fentanyl or morphine increments with propofol to
provide a “balanced” deeper sedation level. Give
rocuronium 0.5–1.0 mg/kg through a reliable i.v.
line; ensure the line is flushed.
2. Set the ventilator to SIMV-PC mode with the
appropriate aforementioned settings.
3. Reduce the PEEP to 4 cmH2O less than the current
PEEP setting. The CURE software cannot estimate
an optimal PEEP that is lower than the current
PEEP setting.
4. Start PUMP on the CURE soft programme.
5. Follow the steps of the CURE soft PUMP protocol.
During the PUMP procedure, increase PEEP in two
steps of 4 cmH2O. Then decrease PEEP in two
steps of 4 cmH2O (you may need to adjust the FiO2
to keep the SpO2 ≥ 90%).
6. Once you have returned PEEP to the starting PEEP
level (initial PEEP − 4 cmH2O), perform a second
PUMP using the same method described in point 5.
7. The CURE soft programme will recommend a new
PEEP at the end of the second PUMP. You may
either accept this computerised recommendation,
or reject it (with a reason) if you feel the new PEEP
level is inappropriate. If rejected, record your
reason(s) on the programme.
8. Return the patient to the previous ventilation mode.
9. Adjust to VT ≤ 6–8 ml/kg IBW. If the plateau
pressure is > 30 cmH2O, adjust the VT down to 4–
6 ml/kg IBW and tolerate permissive hypercapnia.
Also ensure that the DP remains ≤15 cmH2O. You
may increase the respiratory rate up to 30 breaths/
min provided there is no significant auto-PEEP
causing breath stacking.
10. Reduce the ETT cuff pressure to the previous level
and re-set ventilator alarms to previous settings.
11. Take an ABG 30 to 60 mins following the
conclusion of the procedure
Standard practice SRM
Participants assigned to SPV have PEEP determined
using clinical judgement, as per local unit standard care.
However, if oxygen requirements are high or have re-
cently increased e.g. an FiO2 ≥ 50% to keep SpO2 in the
target range of 93–95%, the following should be consi-
dered if the treating clinician is intending to carry out an
SRM:
1. Patient conditions for which lung recruitment are
contraindicated are excluded (e.g. endobronchial
intubation, mucous plugging, pneumothorax etc.)
2. Analgesia and sedation, and patient position have
been optimised
3. Small changes to respiratory rate, VT, pressure
support or neuromuscular blockade to optimise
mechanical ventilation
If the oxygenation does not improve with the afore-
mentioned interventions, then PEEP may be increased in
increments of 2 cmH2O. If the PEEP is ≥ 15 cmH2O and
FiO2 is ≥ 60%, (P/F ~ 100) in spite of addressing the
aforementioned points, a staircase recruitment
manoeuvre (SRM) may be considered if the clinician
feels this is in the best interests of the patient.
The SRM procedure does not utilise the CURE soft-
ware to perform recruitment and therefore the software
will not guide the user, nor make any PEEP suggestions.
The software will still record airway pressure and flow
through this procedure.
To ensure a SRM, can be safely carried out, the RM
checklist and preparation steps are to be followed. If the
checklist preconditions are met, the SRM may be carried
out (note, the SRM procedure does not utilise CURE
software to perform recruitment).
The following instructions are given to the clinician:
1. Titrate sedation so the patient is not verbally
responsive and has loss of their eyelash reflex. Use
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fentanyl or morphine increments with propofol to
provide a “balanced” deeper sedation level. Give
rocuronium 1.0–1.5 mg/kg through a reliable i.v.
line; ensure the line is flushed.
2. Set the ventilator to SIMV-PC mode.
3. Set Pi to 15 cmH2O above PEEP.
4. Ensure the initial PEEP is ≤ 15 cmH2O. If PEEP is
set at ≤ 15 cmH2O, the corresponding plateau
pressure will not exceed 30 cmH2O.
5. Increase PEEP in a stepwise manner every minute
in steps of 4 cmH2O to a achieve Pi of 40–43
cmH2O.
6. Reduce PEEP to 24, and then by decrements of 2
cmH2O, every 2 min, until the SpO2 begins to fall
by no less than 2% of the maximum observed. Hold
PEEP at this level and then increase PEEP to the
maximum that was previously used for 1 min
before returning to a PEEP level 2 cmH2O above
the level when the SpO2 was first noted to have
fallen (the decrements in 2 cmH2O will allow a
PEEP selection between 16 and 24 cmH2O, which is
within the high PEEP protocol from the ARDS
Clinical Network study of high versus low PEEP [4].
7. If there is no desaturation during the decremental
phase of the SRM, reduce PEEP to 16 cmH2O; no
further changes in PEEP are required.
8. Return the patient to the previous ventilation mode.
9. Adjust the DP to ≤ 15 cmH2O to give a VT ≤ 6–8
ml/kg IBW. If the plateau pressure is > 30 cmH2O,
adjust the DP so that VT is to 4–6 ml/kg IBW and
tolerate permissive hypercapnia. You may increase
the respiratory rate up to 30 breaths/min provided
there is no significant auto-PEEP causing breath
stacking.
10. Reduce the ETT cuff pressure to the previous level
and re-set ventilator alarms to previous settings.
Record ABGs 30–60 mins after the conclusion of
the procedure.
Ventilator dyssynchrony
Ventilator dyssynchrony occurs when a patient’s spontan-
eous respiratory efforts are not synchronised with the ven-
tilator. This commonly causes agitation and respiratory
distress; often described as “fighting the ventilator”. Dys-
synchrony should be considered in patients with increased
respiratory efforts, unexplained agitation, tachycardia, or
sweating. Ventilator wave forms can be used to identify
dyssynchrony.
In participants assigned to MBV, dyssynchrony will often
cause large spikes in the elastance recordings. The CURE
soft algorithm does not account for patient breathing efforts
and “sees” inspiratory effort as a rapid reduction in lung
elastance [32, 33]. In contrast, coughing, breath-holding, and
other dyssynchronous efforts may cause an apparent
increase in elastance [34]. Figure 2 shows an example of
ventilator dyssynchrony in a pressure-controlled mode. Dys-
synchrony may be seen as negative deflections (“M” waves)
in the flow-time waveform, as shown in Fig. 2. In contrast
the airway pressure may only be changed minimally by pa-
tient effort.
It is important to exclude reversible mechanical causes
that might lead to patient distress and ventilator dys-
synchrony. Endobronchial intubation, obstruction of a
major bronchus or pneumothorax should be excluded.
Usually ventilator dyssynchrony can be managed by in-
creasing sedation. However, in many cases it may be
preferable to use intermittent muscle relaxants to fully
control ventilation. It also may be helpful to trial the pa-
tient on assisted spontaneous breathing (ASB) to im-
prove ventilation synchrony, if PEEP is ≤ 10 cmH2O and
the FiO2 is ≤ 40%. However, caution should be exercised,
lest the patient become exhausted (see “Weaning”).
Weaning assessment
These guidelines are a pragmatic and consistent way to
transition patients to ASB. Weaning is challenging and diffi-
cult to protocolise because there are many different factors
to consider. For this reason, the weaning process is typically
determined by clinical judgement. However, the guidelines
presented here are set to ensure consistency of care.
ASB is considered when the participant’s condition is
improving. They should preferably be afebrile, have reso-
lution of the underlying processes that led to their ICU
admission and improving gas exchange. They should
have improving muscle strength, decreasing sedation re-
quirements with an improving Glasgow Coma Score
(GCS) and Richmond Agitation Sedation Score (RASS)
between −3 and +1. Generally, the FiO2 should be ≤ 40%
and PEEP ≤ 10 cmH2O.
If the following are substantially present, then partici-
pants may be transitioned to ASB:
1. Improving condition
2. Minute ventilation acceptable (VE) ≤ 0.2 L/kg
3. FiO2 ≤ 40%
4. SpO2 93–95%
5. pH ≥ 7.3
6. Heart rate ≤ 120 beats/min
7. Low vasoactive drug requirements (noradrenaline +
adrenaline ≤ 10 mcg/min)
The following instructions or recommendations are
used to guide transition to ASB:
1. Set mandatory respiratory rate (RR) at ≤ 10 cmH2O.
2. Set pressure support (PS) at 10–15 cm cmH2O.
3. Consider PEEP level.
a. Generally, keep PEEP at ≤ 10 cmH2O.
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b. PEEP maybe up to 15 cmH2O in obese
participants or when the chest wall or
abdominal elastance is increased.
4. Monitor RR, HR and SpO2 over the next 30 min. If
there is significant increase in distress, desaturation,
or an increased oxygen requirement, the participant
is reverted back to the previous controlled
ventilation mode.
5. If there is no significant deterioration, change the
ventilation mode to ASB.
6. If the participant is comfortable, you may reduce
PEEP and PS after 12 h. Titrate PEEP and PS as
clinically indicated by ≤ 2 cmH2O PEEP; PS should
remain at ≥ 5 cmH2O. Reductions in PEEP and PS
should be generally made between 0800 and 1800
hours.
Observations during ASB
The following observations should be made:
1. Check RR, HR and SpO2 every 2 h:
a. If there are increases in heart rate, agitation,
delirium, respiratory distress, minor
desaturations, or increasing oxygen
requirements (ΔFiO2 ≥ 10% or FiO2 ≥ 50%),
check the patient and the ventilator;
i. Exclude patient conditions, e.g.
endobronchial intubation, mucous plugging,
pneumothorax etc.;
ii. Optimise analgesia/sedation and patient
position;
iii. Consider increasing
– Pressure support up to 15 cm;
– Expiratory time for triggering (e.g.
adjusting E sens up to 50% on the PB840
ventilator);
– Triggering sensitivity;
b. If the FiO2 is ≥ 50% or the FiO2 has increased
by ≥ 10% in the previous 2 h, consider adjusting
PEEP up (or down) by ≤ 2 cmH2O. Consider
repositioning the patient and optimising
sedation;
c. If secretions are obstructing large airways, or
there are significant regions of consolidation,
these conditions are unlikely to respond to
increases in PEEP and increases in PEEP may
impair oxygenation. Thus, if the PEEP is > 10
cmH2O, consideration should be given to
reducing it;
d. If the aforementioned measures do not improve
oxygenation, re-sedate and revert back to the
previous controlled ventilation mode (Bi-Level
or PC-SIMV+ or equivalent);
e. If the oxygenation has not improved after 12 h on
controlled ventilation, or there is an
unanticipated new problem causing deterioration,
the participant should return to their previously
assigned ventilation arm (MBV or SPV), e.g.:
iv. New lung injury/de-recruitment/aspiration/
sepsis.
v. Haemodynamic instability.
vi. Need to return to the operating room or to
undergo invasive procedure.
2. If there is continual improvement, proceed towards
separation from mechanical ventilation (extubation
or continuous positive airway pressure (CPAP) via a
tracheostomy).
Patient enrolment and data management
A simplified flow chart of the patient enrolment process can
be found in Additional file 1. All study data, including venti-
lation data, patient and family/friend consent, SAE reports
and other documentation will be stored in a repository.
Consolidated standards of reporting trials (CONSORT)
Figure 3 shows the CONSORT diagram for the CURE RCT.
Data acquisition and management
Patients recruited into the CURE RCT will have the fol-
lowing data collected.
Fig. 2 An “M” wave is seen in the flow-time waveform (flow starvation), followed by a spontaneous (pressure-supported) breath
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Patient demographic and history
The following data will be collected:
1. Patient gender, height, weight and ethnicity
2. Primary patient diagnosis contributing to ARDS or
impaired lung function
3. Secondary patient diagnosis contributing to ARDS
or impaired lung function
4. Relevant past medical history, e.g. smoking,
medication, cardiovascular disease
5. Chest x-ray score derived by the Murray Index [35]
Patient mechanical ventilation data
Data on patient airway pressure and flow generated from
the mechanical ventilator will be recorded using the
CURE software (CURE Soft.) provided with the RCT.
The patient data are backed up regularly to external
storage with encryption applied using VeraCrypt encryp-
tion software [36].
Other patient information
The following information will be collected:
1. Demographic data
a. Age, weight, height
b. Ethnicity
c. Acute Physiology and Chronic Health
Evaluation (APACHE) II and IIIJ, Simplified
Acute Physiology Score (SAPS) II, Australian
and New Zealand Risk of Death (ANZROD)
from the ANZICS CORE database
2. Waveform data from physiological monitors
including:
a. SpO2 - used to detect desaturation events
Fig. 3 Consolidated standards of reporting trials (CONSORT) diagram for the CURE randomized controlled trial (RCT). P/F, partial pressure of
arterial oxygen/fraction of inspired oxygen; PEEP, positive end-expiratory pressure; FiO2, fraction of inspired oxygen; COPD, chronic obstructive
pulmonary disease; PAO2, partial pressure of arterial oxygen; LoMV, length of time of mechanical ventilation; VFD, ventilator-free days; SPO2,
oxygen saturation; ECMO, extracorporeal membrane oxygenation




3. Arterial blood gases:
a. Measured at least twice daily
b. Before and after any RMMax or PUMP
4. Routine biochemical analysis (up to daily)
a. Electrolytes, urea, creatinine, glucose, liver tests
b. Full blood count
5. Patient’s findings on radiology (chest x-ray and
computed tomography (CT))
6. Patient position during MV (to account for data
variation resulting from changes in patient position)
7. Rescue therapies: (i) prone positioning, (ii) nitric
oxide (iii) ECMO
8. Length of time of mechanical ventilation (LoMV)
or ventilation-free days
9. Amount of sedation - to account for possible data
variation resulting from use of different sedatives
10. Duration of ICU stay
11. Frequency and duration of renal support therapies
12. All causes of ICU, hospital and 90-day mortality
Blood samples
No person or authority will have access to the partici-
pant’s blood. The blood samples are not stored. They
are discarded and incinerated as soon as practicable, in
accordance with NZS 4304:2002 “Healthcare Waste
Management”.
Data management
All CURE RCT data will be stored at the University of
Canterbury (UC). All paper forms (patient sheets, con-
sent forms, etc.) will be scanned and stored at the UC.
All electronic data will be stored in double-encrypted re-
pository and only the participating researchers have ac-
cess to it. Currently there are no plans for sharing the
data, but if requested, data may be shared. Participants
in the study can request their copy of data.
The data will be backed up weekly and again, once the
participant has finished the trial and left the hospital.
This task will only be performed by the participating
researchers. Any protocol variations will be followed up
and noted. The CURE RCT will store data for 20 years.
Study outcome
The trial will utilise a primary composite end point in-
corporating the AUC of the P/F ratio over the period of
MV. Every participant in the intervention (MBV) group
is compared with every participant in the control (SPV)
group. Test statistics will be calculated using the one-
sided Wilcoxon rank sum test at alpha of 0.05. If results
show no statistically significant difference between the
intervention and control, it will result in the rejection of
the intervention treatment as a standard of care and
thus, the secondary clinical outcome assessments will in-
clude the number of desaturation events measured as
peripheral capillary oxygen saturation < 90%, LoMV,
VFD for 28 days, the quality of mechanical ventilation
care measured as the AUC of SpO2/FiO2 and chest x-ray
index scores over time. The test statistic will be calcu-
lated using the one-sided Wilcoxon rank sum test at
alpha of 0.05.
A difference in the primary outcome will show the im-
pact of MBV compared to SPV. No difference would show
that enhanced, model-based metrics of the patient-specific
condition have no effect on patient-centred or clinical out-
comes. Either outcome will yield clinical guidance.
Sample size study
A Monte-Carlo simulation was performed to determine
the sample size and determined that a minimum effect-
ive sample size of approximately 160 patients per arm is
required to identify a 25% reduction in median LoMV,
with 0.8 power, at a double-sided significance level of
5% [37].
Stopping rule
A linear alpha spending approach will be used for early
termination of the trial for safety. Linear alpha spending
falls between a Pocok and O’Brien-Fleming boundary
[38]. With analysis points of 50, 75, 100, 125 and 160
patients per arm, and assumed control group mortality
of 0.2, the mortality difference required to stop the trial
(MortalityIntervention – Mortalitycontrol) at each analysis
point respectively is 0.20, 0.16, 0.14, 0.12 and 0.10. This
approach has cumulative α = 0.025.
Safety, ethics and dissemination
Ethics approval has been filed with the New Zealand Na-
tional Health and Disability Ethics Committee. The
CURE RCT clinical protocol and data usage has been
filed with the New Zealand South Regional Ethics Com-
mittee (reference number 14/STH/132). The CURE trial
is also registered in the Australian New Zealand Clinical
Trial Registry (ACTRN12614001069640).
All results and any subsequent analysis will be pub-
lished and only the participating investigators will be
authors. Currently there is no plan to share data with
other organisations. The data collected in this study will
also be used for future research.
Adverse event (AE) and SAE reporting
(AEs are defined as any unexpected change in physiology in
a study participant associated with either the RMmax or
PUMP. This does not necessarily have to have a causal rela-
tionship with the aforementioned procedures. Typically, this
would be an unexpected, non-life-threatening event, which
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rapidly resolves following simple corrective measures. For
example, hypotension will occur in most participants under-
going an RMmax or PUMP. However, if the procedure had
to be shortened or abandoned, but the participant recovered
with simple corrective measures (e.g. temporarily increasing
noradrenaline by ≥ 5 mcg/min) or giving > 500ml fluid
bolus) this would be recorded as an AE. It is very important
these events are accurately recorded as risk factors for AEs
that need to be defined when carrying out RMs (as seen in
Additional file 3).
SAEs are defined as any untoward medical occur-
rence that (1) results in death; (2) is life-threatening;
(3) prolongs hospitalisation or (4) results in disability
or incapability. However, baseline mortality in the pa-
tients in intensive care who are enrolled in the trial
will likely be high due to the critical illness necessi-
tating admission to the ICU. Despite attempts at pre-
vention, trial participants will frequently develop life-
threatening organ failure(s) unrelated to study inter-
ventions. Events that are a part of the natural history
of the primary disease process or expected complica-
tions of critical illness will not be reported as SAEs
in this trial. Additionally, events already defined and
reported as study outcomes, such as mortality or re-
admission to the ICU, will not be labelled and re-
ported separately as SAEs unless they are considered
to be causally related to the study intervention or are
otherwise of concern in the investigator’s judgement.
SAEs will be reported to the principal investigator
within 24 h of any investigator becoming aware of the
event. The minimum information to report includes:
 Patient trial identifier
 The nature of the event
 The time the event commenced and ceased
 An investigator’s opinion of the relationship between
study involvement and the event (not related,
unlikely, possibly, probably or definitely related)
 Whether treatment was required for the event and
what treatment was administered
SAEs could include pneumothorax, hypotension lead-
ing to cardiac arrest, transient desaturation leading to
severe or prolonged desaturation, tachycardia, bradycar-
dia, arrhythmia, anaphylaxis and unintended protocol
deviations.
In the unlikely event of a physical injury to the partici-
pant as a result of their participation in this study, they
will be eligible to apply for compensation from the Acci-
dent Compensation Corporation (ACC) NZ within its
limitations. If the participant’s family/friend have any
questions about the ACC, they will be able to ask the re-
searchers for more information before they agree to take
part in this trial.
ACC cover is not automatic and their case will need to
be assessed by the ACC according to the provisions of
the 2001 Injury Prevention Rehabilitation and Compen-
sation Act. If the claim is accepted by the ACC, the pa-
tient still might not receive compensation. This depends
on a number of factors such as whether they are earners
or non-earners. The ACC usually provides only partial
reimbursement of costs and expenses and there may be
no lump sum compensation payable. There is no cover
for mental injury unless it is a result of physical injury. If
your relative or friend has ACC cover, generally this will
affect their right to sue the investigators.
Data Monitoring Committee (DMC)
An independent DMC comprising experts in clinical tri-
als, biostatistics and intensive care medicine is estab-
lished before patient enrolment, to review all trial
protocols and oversee and advise on this trial. The DMC
will be forwarded a copy of all SAE reports as soon as
they become available to the trial investigators. The
DMC will review all SAE reports that they receive and
report back to investigators if any further action is
required.
CURE RCT composition
The steering committee of the CURE RCT comprises
the primary investigators Geoff Shaw, Geoff Chase, Chris
Pretty and Yeong Shiong Chiew. The clinical data are
collected by research nurses in the ICU and mechanical
ventilation data and oxygenation (bedside monitor) data
will be collected by researchers from the UC. All study
data will be stored in the double-encrypted repository at
UC. Data will be interpreted by participating researchers.
The open and closed case interim reports will be com-
piled by Paul Docherty every 6months and when 50 and
100 patients have been included. The DMC will have
authority to continue or stop of the trial based on the
interim reports.
Discussion
Mechanical ventilation using PEEP set at minimum elas-
tance has long been investigated in both experimental
and clinical trials. These studies ranged from healthy pa-
tients under general anaesthesia to those with ARDS.
However, only a few studies have investigated the clin-
ical potential of PEEP set at minimum elastance. Recent
studies by Pintado et al. [22] and Chiew et al. [23] have
shown the potential and feasibility of ventilating patients
using minimum elastance PEEP. However, setting PEEP
based on elastance is problematic due to the increased
need of muscle relaxants, protocol burden and potential
contradictory findings [22, 23]. The pilot trial was also
underpowered and thus, a larger clinical trial such as the
CURE RCT is required to provide further insight and
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validate the potential benefit of optimising mechanical
ventilation PEEP with model-based methods.
The CURE RCT implements a protocolised staircase
PEEP recruitment manoeuvre together with novel com-
puter software to calculate respiratory system elastance
in real time. The computer software, CURE Soft [25],
uses a single compartment lung model [39] together
with other model-based approach [24, 40] to aid clini-
cians during PEEP selection. This process potentially re-
duces selected PEEP variability and provides more
consistent clinical guidance.
There are several limitations of the CURE RCT design
that should be noted. In particular, the RM is a double-
staircase manoeuvre and is design specific. Studies have
shown that not all patients benefit from RMs [41, 42],
and the benefit of an RM is dependent on the patient-
specific disease state, as well as the design of the RM.
The double-staircase RM in this trial was designed to as-
sess lung recruitment and provide consistent PEEP titra-
tion. It is noted that not all patients included in this
study will necessarily demonstrate alveolar lung
recruitment.
Another limitation worth noting is the control group
clinical protocol. Clinically, there is relatively little consen-
sus an optimal mechanical ventilation mode. Thus, the
standard practice ventilation in the participating hospital
relies on general approaches [2] and is highly variable be-
tween clinicians. There may be no equal comparator for a
mechanical ventilation study resulting from this variability.
Patients recruited to the CURE RCT will have the MV
mode set to bi-level ventilation in both the intervention
and the control group; it is debatable that bi-level ventila-
tion may lack certain ventilation advantages. However,
this procedure will reduce variability and provides the op-
portunity for fair comparison between groups.
In the participating ICU, there are > 700 patients per
year requiring invasive MV; however, only an average of
< 5 patients were diagnosed with ARDS as the primary
diagnosis per year. ARDS is nearly always regarded as a
complication of an acute process. One concern is that
the desired sample size cannot be achieved. However,
this number is also too small compared to reports [43,
44]. The small number may be due to changes in the
ARDS definition [27, 45] and misdiagnosis [46].
Estenssoro et al. [46] report that misdiagnosis could
occur due to delayed screening. Thus, in the CURE
RCT, any patient requiring invasive mechanical ventila-
tion is screened immediately, as per Villar et al. [27],
whereby the P/F ratio is measured at PEEP = 5 cmH2O,
and FiO2 = 50%. Equally, retrospective screening was also
performed and identified > 200 patients eligible for the
trial per year. Hence, a 3-year study is planned to
achieve the target sample size at an estimated recruit-
ment rate of 50%.
Conclusion
Optimising patient-specific mechanical ventilator set-
tings remains a huge clinical challenge due to patient
disease variability, as well as clinical practice variability.
Thus, there is a need for a method to provide consistent
patient-specific treatment. The CURE RCT is the first
single-centre large clinical RCT using model-based mini-
mum elastance PEEP selection in mechanical ventilation.
It provides a means to select patient-specific PEEP in a
consistent fashion and patient outcomes are compared
to current practice. The CURE RCT investigation group
hope that the results from this trial will support the use
of model-based methods to estimate optimal PEEP, and
will serve as a platform to assess other patient-centred
outcomes in future mechanical ventilation studies in
ARDS/ALI.
Trial status
The trial has not started recruiting yet. The trial is
estimated to start in December 2019 in Christchurch
Hospital Intensive Care Unit. The trial is estimated to be
completed by May 2022. This is protocol version num-
ber 2.0, dated 20 August 2019.
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